LIVE
ALNY
Alnylam Pharmaceuticals, Inc. · Health Care - RNA Interference Therapeutics
$278.09
-5.51% this month
VERSUS
⟷
COMPARE
IONS
Ionis Pharmaceuticals, Inc. · Health Care - Antisense Oligonucleotide Therapeutics
$74.12
+0.38% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
ALNY
2
IONS
2
Comparison scoreboard
MIXED SETUPAI Score
ALNY ✓57.2
IONS 54.1
1Y Return
ALNY -10.96%
IONS ✓+100.27%
Fwd P/E
ALNY 20.20
IONS ✓-99.66
Target Up.
ALNY ✓+56.90%
IONS +41.54%
Op. Margin
ALNY N/A
IONS N/A
Metrics last refreshed: 6/20/2026
Quick take
ALNY vs IONS Stock Comparison: AI Score, Valuation, Performance and Upside
ALNY and IONS are the two foundational RNA drug companies, using different molecular mechanisms — RNAi (Alnylam) versus ASO (Ionis) — to silence disease-causing genes. Both compete directly in ATTR amyloidosis and share the broader RNA therapeutics space with multiple programs, but differ in their commercial maturity and pipeline monetization strategies.
ALNY vs IONS compares the two pioneering RNA drug companies, both targeting genetic diseases through RNA-based mechanisms but with different platform technologies, commercial portfolios, and business models.
Live analysis · updated 6/20/2026
ALNY and IONS are closely matched — they split the tracked metrics evenly. IONS leads on both 1-year return (+100.27%) and forward P/E (-99.66x vs 20.20x for ALNY), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for ALNY (+56.90%) than for IONS (+41.54%).
Normalized 1Y performance
ALNY
IONS
Recent returns
ALNY
IONS
Analyst price targets & sentiment
ALNY · 25 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.8/5.0)
Price target range
analyst low$310.00
analyst high$550.00
analyst mean$436.32
current price$278.09
+56.9% upside to analyst mean
IONS · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.6/5.0)
Price target range
analyst low$74.00
analyst high$130.00
analyst mean$104.91
current price$74.12
+41.5% upside to analyst mean
Who should consider this stock?
ALNY may suit investors who:
- →Want exposure to the commercial leader in RNAi therapeutics with multiple approved drugs
- →Believe Amvuttra and Leqvio will build into large, durable commercial franchises
- →Value Alnylam's direct commercialization track record across its approved product portfolio
IONS may suit investors who:
- →Want exposure to the pioneer of antisense oligonucleotide technology with the broadest RNA pipeline
- →Value the royalty and milestone income from Ionis's many partnered programs
- →See opportunity as Ionis transitions toward greater proprietary drug commercialization
Performance & AI score
| Metric | ALNY | IONS |
|---|---|---|
| AI score | 57.2 | 54.1 |
| AI rank | #219 | #287 |
| Latest close | $278.09 | $74.12 |
| 1M return | -5.51% | +0.38% |
| 6M return | -29.08% | -3.84% |
| 1Y return | -10.96% | +100.27% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ALNY | IONS |
|---|---|---|
| 1Y ago | $8.9K (-11.0%) started 2025-06-18 | $20.03K (+100.3%) started 2025-06-18 |
| 5Y ago | $15.72K (+57.2%) started 2021-06-18 | $19.61K (+96.1%) started 2021-06-18 |
| 10Y ago | $49.1K (+391.0%) started 2016-06-20 | $32.17K (+221.7%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | ALNY | IONS |
|---|---|---|
| Market cap | $37.13B | $12.25B |
| Trailing P/E | 70.05 | N/A |
| Forward P/E | 20.20 | -99.66 |
| Price/Sales | 8.66 | 11.58 |
| EV/Revenue | 8.77 | 12.01 |
| Analyst target | $436.32 | $104.91 |
| Target upside | +56.90% | +41.54% |
Growth, profitability & risk
| Metric | ALNY | IONS |
|---|---|---|
| Revenue growth | 96.40% | 87.00% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | +4.78% | -76.34% |
| Operating margin | N/A | N/A |
| Profit margin | 12.55% | -30.90% |
| ROIC proxy | 90.36% | -67.62% |
| Return on equity | 90.36% | -67.62% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 0.27 | 0.37 |
| Debt/equity | 276.20 | 531.05 |
| Current ratio | 3.13 | 4.10 |
| Quick ratio | 2.88 | 2.86 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
ALNY max drawdown43.39%
IONS max drawdown19.45%
ALNY max wkly drop14.54%
IONS max wkly drop8.76%
5Y risk snapshot
ALNY max drawdown43.39%
IONS max drawdown52.36%
ALNY max wkly drop20.65%
IONS max wkly drop17.36%
10Y risk snapshot
ALNY max drawdown59.95%
IONS max drawdown70.39%
ALNY max wkly drop49.44%
IONS max wkly drop23.51%
Performance metrics by period
| Period | Metric | ALNY | IONS |
|---|---|---|---|
| 1Y | Growth | -10.96% | +100.27% |
| CAGR | -10.97% | +100.37% | |
| Sharpe ratio | -0.25 | 1.61 | |
| Max drawdown | 43.39% | 19.45% | |
| Max daily drop | 6.87% | 5.48% | |
| Max wkly drop | 14.54% | 8.76% | |
| 5Y | Growth | +57.21% | +96.14% |
| CAGR | +9.47% | +14.42% | |
| Sharpe ratio | 0.32 | 0.42 | |
| Max drawdown | 43.39% | 52.36% | |
| Max daily drop | 17.10% | 13.82% | |
| Max wkly drop | 20.65% | 17.36% | |
| 10Y | Growth | +390.98% | +221.70% |
| CAGR | +17.26% | +12.40% | |
| Sharpe ratio | 0.48 | 0.38 | |
| Max drawdown | 59.95% | 70.39% | |
| Max daily drop | 48.49% | 21.66% | |
| Max wkly drop | 49.44% | 23.51% |
Business comparison
| Category | ALNY | IONS |
|---|---|---|
| Company | Alnylam Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. |
| Sector | Health Care - RNA Interference Therapeutics | Health Care - Antisense Oligonucleotide Therapeutics |
| Industry | N/A | N/A |
| Core business | Alnylam pioneered RNA interference (RNAi) therapeutics, using small interfering RNA (siRNA) to silence disease-causing genes, with an approved commercial portfolio including Onpattro, Givlaari, Oxlumo, Leqvio, and Amvuttra for rare genetic diseases and cardiovascular conditions. | Ionis is a pioneer in antisense oligonucleotide (ASO) technology, having developed one of the largest portfolios of RNA-targeted medicines, including approved drugs for spinal muscular atrophy (through partner Biogen) and ATTR amyloidosis, plus dozens of partnered and proprietary clinical programs. |
| Investor focus | Investors track Amvuttra's growth in ATTR amyloidosis, Leqvio's revenue ramp in cardiovascular cholesterol reduction, and the advancement of new siRNA programs into clinical development. | Investors track Ionis's proprietary product revenue from Wainua (eplontersen, ATTR amyloidosis), royalties from partnered drugs, and the breadth of its clinical pipeline spanning neurology, cardiology, and rare diseases. |
ALNY strengths
- →Pioneer and leader in RNAi therapeutics with multiple approved drugs across rare and cardiometabolic disease
- →Amvuttra and Leqvio represent potentially large commercial opportunities in ATTR amyloidosis and cardiovascular disease
- →siRNA technology platform enables efficient creation of new drug candidates from validated genetic targets
IONS strengths
- →One of the longest-established RNA drug pioneers with decades of ASO platform expertise
- →Broad partnered pipeline across major pharmaceutical companies generates royalties and milestone payments
- →Proprietary programs provide upside beyond royalties as Ionis transitions to direct drug commercialization
Risks to watch — ALNY
- →ATTR amyloidosis market is contested with competition from BridgeBio and others
- →Leqvio's commercial ramp in cardiovascular has been slower than initially expected
- →RNAi drugs require specialized delivery systems and ongoing clinical safety monitoring
Risks to watch — IONS
- →Ionis is transitioning from a partner-dependent royalty model toward direct drug commercialization, which requires significant investment
- →Wainua competes directly with Alnylam's Amvuttra in ATTR amyloidosis
- →Large pipeline creates complexity in prioritizing investor focus across dozens of programs
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →